Wellgistics Health, Inc. has launched its diabetes drug Brenzavvy® to its pharmacy network, targeting the $16 billion SGLT-2 inhibitor market in the US. The company uses its EinsteinRx™ AI platform to assist pharmacists with patient education, aiming to reduce out-of-pocket costs and enhance patient access. This launch establishes a new model for reformulated drug introductions in the market.

WGRX

<p>Wellgistics Health, Inc. 已經向其藥房網絡推出了糖尿病藥物 Brenzavvy®，瞄準美國 160 億美元的 SGLT-2 抑制劑市場。該公司利用其 EinsteinRx™ AI 平台幫助藥劑師進行患者教育，旨在降低患者自付費用並增強患者的可及性。這一推出為市場上重新配方藥物的引入建立了新的模式</p>

Wellgistics Health 推出了糖尿病藥物 Brenzavvy®